Clinical Trials on Gastric/Gastroesophageal Junction Cancer

Total 2859 results

Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

China
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Cancer Third Line

Spain, Italy, Australia, Korea, Republic of, Belgium, France, Poland, United States, Czechia, Germany
Servier Bio-Innovation LLC
Merck Sharp & Dohme LLC; Institut de Recherches Internationales Servier

Not yet recruiting

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

MSI-H/dMMR Gastroesophageal-junction Cancer | MSI-H/dMMR Gastric Cancer
Maxinovel Pty., Ltd.

Recruiting

A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer

Gastric Cancer | Gastroesophageal Junction Cancer

China
Memorial Sloan Kettering Cancer Center

Terminated

Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer

Gastric Cancer | Gastroesophageal Junction Cancer

United States
Hoffmann-La Roche

Completed

A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer (TOXAG)

Gastric Cancer | Gastroesophageal Junction Cancer

Turkey
Cancer Institute and Hospital, Chinese Academy...

Unknown

Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer

Gastric Cancer | Gastroesophageal Junction Cancer

China
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

Gastric Cancer | Gastroesophageal Junction Cancer

United States, Belgium, Brazil, Canada, Chile, China, Estonia, France, Germany, Guatemala, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Malaysia, Philippines, Poland, Russian Federation, Singapore, Taiwan, Ukraine, United...
Sumitomo Pharma America, Inc.

Completed

A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer (BRIGHTER)

Gastric Cancer | Gastroesophageal Junction Cancer

United States, Hungary, Spain, China, Brazil, France, Australia, Czechia, Germany, Israel, Canada, United Kingdom, Japan, Belgium, Romania, Italy, Poland, Lithuania, Korea, Republic of, Bulgaria, Estonia, Russian Federation
Hoffmann-La Roche

Completed

Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea

Gastric Cancer | Gastroesophageal Junction Cancer

Korea, Republic of
Shanghai Miracogen Inc.

Recruiting

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.

Advanced or Metastatic Gastric Cancer | Advanced or Metastatic Gastroesophageal Junction Carcinoma

China
M.D. Anderson Cancer Center

Recruiting

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

Gastrostomy | GastroEsophageal Cancer | Gastric

United States, Japan, Korea, Democratic People's Republic of
Amgen

Completed

A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer

Gastric or Gastroesophageal Cancer

Japan
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer. (FORTITUDE-103)

Gastric Cancer | Gastroesophageal Junction Cancer

Korea, Republic of, Taiwan, Japan, Singapore, United States
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension

Gastric Cancer | Gastroesophageal Junction Cancer

China
Hellenic Cooperative Oncology Group
Boehringer Ingelheim

Completed

Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer (A-GAPP)

Gastric Cancer | Gastroesophageal Junction Cancer

Greece
Fudan University

Recruiting

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer (Miracle-G)

Adenocarcinoma | Metastatic Cancer | Metastatic Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Oligometastatic Disease | Stomach Neoplasm | Adenocarcinoma of the Stomach | Gastroesophageal-junction Cancer | Metastatic Adenocarcinoma

China
Hoffmann-La Roche

Active, not recruiting

An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma

Gastric and Gastroesophageal Junction Carcinoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IV Esophageal Adenocarcinoma AJCC v8 and other conditions

United States
BeiGene

Active, not recruiting

Anti-HER2 Bispecific Antibody ZW25 Activity in Combination With Chemotherapy With/Without Tislelizumab

Breast Cancer | Gastric Cancer | Gastroesophageal Junction Cancer

China, Taiwan, Korea, Republic of
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Active, not recruiting

KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer

Breast Cancer | Gastric/Gastroesophageal Junction Cancer

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer

China
Wuhan Union Hospital, China

Recruiting

Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC

Advanced Gastric Cancer | Advanced Gastroesophageal Junction Adenocarcinoma

China
Akeso

Active, not recruiting

A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
CStone Pharmaceuticals

Completed

A Study of CS1001 in Subjects With Gastric Adenocarcinoma or Gastro-Esophageal Junction Adenocarcinoma

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

China
National Cancer Center, Japan
Ono Pharmaceutical Co. Ltd; Fiverings Co., Ltd.

Completed

A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer

Gastric Cancer | Gastroesophageal Junction Region (GEJ) Cancer

Japan
Harbin Medical University

Not yet recruiting

AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
Legend Biotech USA Inc

Recruiting

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma

Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Gastroesophageal-junction Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction Adenocarcinoma | Postneoadjuvant Therapy Stage III... and other conditions

United States
Bavarian Nordic

Active, not recruiting

TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

Chordoma | HER2-positive Breast Cancer | HER2-positive Gastric/Gastroesophageal Junction Cancer

United States
GC Cell Corporation

Not yet recruiting

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Breast Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Australia
Artiva Biotherapeutics, Inc.

Not yet recruiting

A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

Breast Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, United States
The Affiliated Hospital of Qingdao University

Recruiting

Toripalimab Combined With Anlotinib for Patients With Advanced, Relapsed, or Refractory Gastric, or Esophagogastric Junction Cancer (EGJC)

Gastric or Gastro-oesophageal Junction Carcinoma | Advanced, Relapsed Gastric or Gastro-oesophageal Junction Carcinoma | Second-line Therapy

China
Ruijin Hospital

Active, not recruiting

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

China
National Cancer Institute (NCI)

Completed

Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

Metastatic Gastric Cancer | Adenocarcinoma of the Gastroesophageal Junction | Advanced Unresectable Gastric Cancer

United States
Peking University

Not yet recruiting

Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ

Gastroesophageal Junction Cancer | Chemoradiotherapy | PD-1
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer

Adenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer

United States
Suzhou Immunofoco Biotechnology Co., Ltd
Changhai Hospital

Recruiting

Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

Gastric Cancer | Pancreatic Cancer | Gastroesophageal Junction Adenocarcinoma | Advanced Ovarian Carcinoma

China
Xiaofeng Chen

Recruiting

XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study

Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

China
Novartis Pharmaceuticals

Completed

Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

Advanced Gastric Cancer | Gastro-esophageal Junction Cancer

United States, France, Italy, Taiwan, United Kingdom, Turkey, Germany, Singapore, Australia, Russian Federation, Korea, Republic of, Switzerland, Netherlands, Canada
Federation Francophone de Cancerologie Digestive
Eli Lilly and Company

Active, not recruiting

Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients (SOCRATE)

Stomach Cancer | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Stomach Neoplasm

France
Yonsei University

Completed

Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer

Gastric Cancer | Gastroesophageal Junction Cancer

Korea, Republic of
Kuhnil Pharmaceutical Co., Ltd.
Daiichi Sankyo Co., Ltd.

Terminated

Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer

Gastric Cancer | Gastroesophageal Junction Cancer

Taiwan, Japan, Korea, Republic of
Millennium Pharmaceuticals, Inc.

Terminated

MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Recurrent Gastric Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Advanced Gastrointestinal Carcinoma | Recurrent Gastrointestinal Carcinoma

Taiwan, Korea, Republic of, Japan
Sichuan University

Unknown

Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (CTSCAPOXSEA)

Metastatic Gastric Cancer | Gastroesophageal Junction Adenocarcinoma | Stomach Adenocarcinoma | Locally Advanced Unresectable Gastric Adenocarcinoma

China
Second Affiliated Hospital, School of Medicine,...
TCRx Therapeutics Co.Ltd

Not yet recruiting

TCRx_T Cells for Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemotherapy

Gastric Cancer | Gastroesophageal-junction Cancer
University of Chicago

Terminated

Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8 | Pathologic Stage... and other conditions

United States

Clinical Trials on Gastric/Gastroesophageal Junction Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations